Zobrazeno 1 - 10
of 278
pro vyhledávání: '"H. C. Sullivan"'
Autor:
M Attieh, E A Dent, C E Then, E Barrette, D N Alter, A Duncan, J D Roback, H C Sullivan, L Happney
Publikováno v:
American Journal of Clinical Pathology. 158:S160-S160
Introduction/Objective Platelet refractory (PR) patients do not achieve expected post-transfusion platelet counts. We investigate such patients with a post-transfusion platelet count, indirect Platelet Antibody Screen (ind-PAS), Class I HLA Antibody
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1875d55e7715fa17b5dc3d869d197223
https://doi.org/10.1093/ajcp/aqac126.340
https://doi.org/10.1093/ajcp/aqac126.340
Publikováno v:
European Journal of Neurology. 19:307-311
Background: Alemtuzumab (CD52-specific humanized monoclonal antibody) was found to be an effective therapy for treatment-naive patients with relapsing-remitting multiple sclerosis. Objective: Evaluate alemtuzumab’s effects in patients with treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::14ae9352cc2e04340309b17099713cd8
https://doi.org/10.1111/j.1468-1331.2011.03507.x
https://doi.org/10.1111/j.1468-1331.2011.03507.x
Autor:
Błoński, Piotr Jan1,2,3 (AUTHOR) s085001@student.wum.edu.pl, Rutkowski, Piotr1 (AUTHOR) piotr.rutkowski@nio.gov.pl, Ostaszewski, Krzysztof1 (AUTHOR) krzysztof.ostaszewski@nio.gov.pl, Krotewicz, Maria1 (AUTHOR) maria.krotewicz@nio.gov.pl, Czarnecka, Anna M.1 (AUTHOR) annamalgorzata.czarnecka@nio.gov.pl
Publikováno v:
Journal of Clinical Medicine. Nov2024, Vol. 13 Issue 22, p6922. 14p.
Autor:
John N. Whitaker, P. Gjörstrup, Fred D. Lublin, A. Linde, Jerry S. Wolinsky, H. C. Sullivan, Ponnada A. Narayana, John H. Noseworthy
Publikováno v:
Neurology. 54:1734-1741
Objective: To determine the safety and efficacy of roquinimex (linomide) in the management of relapsing-remitting and secondary progressive MS as monitored by MRI. Background: Preclinical studies and several short term randomized trials of linomide s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4646380334abc644d1061ab0273562b3
https://doi.org/10.1212/wnl.54.9.1734
https://doi.org/10.1212/wnl.54.9.1734
Autor:
H. C. Sullivan, J. S. Wolinsky, John H. Noseworthy, P. Gjorstrup, Fred D. Lublin, A. Linde, J. N. Whitaker
Publikováno v:
Neurology. 54:1726-1733
Objective: To determine whether linomide (roquinimex) is better than placebo in slowing the time to confirmed clinical worsening in patients with relapsing–remitting (RR) and secondary progressive (SP) MS. Methods: In this 27-center, randomized, do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b71cbb8a5ceaa20c83ef46f20c486144
https://doi.org/10.1212/wnl.54.9.1726
https://doi.org/10.1212/wnl.54.9.1726
Autor:
Alasdair Coles, Edward Fox, A. Skoromets, D. A. S. Compston, Susan Moran, M.S. Smith, A. Vladic, David Margolin, I. Stolyarov, Vesna V. Brinar, Stephen Lake, Krzysztof Selmaj, H. C. Sullivan, Jeffrey Palmer, Adam J. Bass, Suzanne Gazda
Publikováno v:
Neurology. 78(14)
To report the long-term safety and efficacy results from CAMMS223 comparing alemtuzumab with interferon β-1a in early, active relapsing-remitting multiple sclerosis (RRMS). What are the long-term effects of alemtuzumab treatment, received 36 to 48 m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fb27aa6aa6ce14a5c6dbf4e4d8fb6e0
https://pubmed.ncbi.nlm.nih.gov/23238846
https://pubmed.ncbi.nlm.nih.gov/23238846
Autor:
Lahti‐Pulkkinen, Marius1,2,3 (AUTHOR) marius.lahti-pulkkinen@helsinki.fi, Lähdepuro, Anna1,4 (AUTHOR), Lahti, Jari1 (AUTHOR), Girchenko, Polina1 (AUTHOR), Pyhälä, Riikka1 (AUTHOR), Reynolds, Rebecca M.1 (AUTHOR), Villa, Pia M.5 (AUTHOR), Laivuori, Hannele6,7,8 (AUTHOR), Kajantie, Eero2,9,10,11 (AUTHOR), Heinonen, Kati1,12 (AUTHOR), Räikkönen, Katri1,13 (AUTHOR)
Publikováno v:
JCPP Advances. Sep2024, Vol. 4 Issue 3, p1-15. 15p.
Publikováno v:
Journal of Chinese Mass Spectrometry Society. Sep2024, Vol. 45 Issue 5, p691-698. 8p.
Publikováno v:
European journal of neurology. 19(2)
Alemtuzumab (CD52-specific humanized monoclonal antibody) was found to be an effective therapy for treatment-naive patients with relapsing-remitting multiple sclerosis.Evaluate alemtuzumab's effects in patients with treatment-refractory relapsing-rem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c6b137ceb30bf1bf52ee8fbe342426ba
https://pubmed.ncbi.nlm.nih.gov/21899662
https://pubmed.ncbi.nlm.nih.gov/21899662
Autor:
J H, Noseworthy, J S, Wolinsky, F D, Lublin, J N, Whitaker, A, Linde, P, Gjorstrup, H C, Sullivan
Publikováno v:
Neurology. 54(9)
To determine whether linomide (roquinimex) is better than placebo in slowing the time to confirmed clinical worsening in patients with relapsing-remitting (RR) and secondary progressive (SP) MS.In this 27-center, randomized, double-blind, placebo-con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3ee127e310e9249d13133598d3a162e8
https://pubmed.ncbi.nlm.nih.gov/10802772
https://pubmed.ncbi.nlm.nih.gov/10802772